Description
The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.
The new edition (BNF 83) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.
Extensive content updates in the BNF 83 edition include:
New monographs for:
- Acarizax® [house dust mite extract] for house dust mite allergic rhinitis or house dust mite allergic asthma
- Adakveo® [crizanlizumab] for vaso-occlusive crises in sickle-cell disease
- Adtralza® [tralokinumab] for atopic eczema
- Bijuve® [estradiol with progesterone] for menopausal symptoms
- Evrenzo® [roxadustat] for symptomatic anaemia associated with chronic kidney disease
- Evrysdi® [risdiplam] for 5q spinal muscular atrophy
- Kesimpta® [ofatumumab] for multiple sclerosis
- Klisyri® [tirbanibulin] for actinic keratosis on face or scalp
- Lagevrio® [molnupiravir] for COVID-19
- Leqvio® [inclisiran] for primary hypercholesterolaemia or mixed dyslipidaemia
- Lumykras® [sotorasib] for non-small cell lung cancer with KRAS G12C mutation
- Ontozry® [cenobamate] for focal seizures with or without secondary generalisation
- Orladeyo® [berotralstat] for hereditary angioedema
- Pemazyre® [pemigatinib] for cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement
- Ponvory® [ponesimod] for multiple sclerosis
- Rukobia® [fostemsavir] for HIV drug-resistant infection
- Ryaltris® [mometasone furoate with olopatadine] for allergic rhinitis
- Ryeqo® [relugolix with estradiol and norethisterone acetate] for uterine fibroids
- Verquvo® [vericiguat] for chronic heart failure with reduced ejection fraction
- Zibor® [bemiparin sodium] for prophylaxis of deep-vein thrombosis in general and orthopaedic surgery, and prevention of clotting in extracorporeal circuits
MHRA advice on:
- Adrenaline/epinephrine auto-injectors: reminder for prescribers to support safe and effective use
- Aflibercept (Eylea®) solution for intravitreal injection: higher risk of intraocular pressure increase with the pre-filled syringe
- Atezolizumab (Tecentriq®) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)
- CDK4/6 inhibitors: reports of interstitial lung disease and pneumonitis, including severe cases
- Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years
- Dapagliflozin (Forxiga®) 5mg should no longer be used for the treatment of type 1 Diabetes Mellitus
- Levothyroxine sodium: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products
- Oral retinoid medicines: temporary monitoring advice during coronavirus (COVID-19) pandemic
- Tofacitinib (Xeljanz®): increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors, and new measures to minimise risk
- Topical corticosteroids: information on the risk of topical steroid withdrawal reactions
- Venetoclax (Venclyxto®): updated recommendations on tumour lysis syndrome (TLS) in chronic lymphocytic leukaemia (CLL) patients
- Yellow fever vaccine, live (Stamaril®): new pre-vaccination checklist
Other significant changes include updated guidance on:
- COVID-19 updated guidance in-line with Public Health England/UK Health Security Agency recommendations, including reports of myocarditis and pericarditis with the Pfizer/BioNTech and Moderna vaccines
- Advice on use of Dapagliflozin in renal impairment, including new indication for chronic kidney disease
- Diabetic hyperglycaemic emergencies
- Direct-acting oral anticoagulants
- Emergency contraception
- Malaria prophylaxis in-line with Public Health England recommendations
- Management of acne
- Management of acute coronary syndromes
- Management of anaphylaxis
- Management of secondary bacterial infection of common skin conditions
- Management of nausea and vomiting during pregnancy
- Prescribing in renal impairment
- Rabies vaccine and post-exposure management
- Recommended insulin regimens in type 1 diabetes
- Tetanus vaccine and the use of immunoglobulin for tetanus infection and prophylaxis in-line with Public Health England recommendations
BNF 83 is an essential publication, it provides you with:
- Up-to-date information on prescribing, dispensing, and administering medicines
- Authoritative, independent guidance on best practice enabling you to select safe and effective medicines
- Information you know you can trust for quality, reliability, and independence
- Everything you need at your fingertips, all in one book
